We suggest that the tools developed in cancer and autoimmune disease research may be applicable to develop DC-based therapeutic to prevent AA progression to attenuate complications of AAs such as dissection of the arterial wall, inhibiting enzymes including proteinases known to be involved in AA complications and by targeting a variety of inflammatory cytokines and mediators of CD8+ cytotoxic T cells. This evidence concerns the gene CD8A and autoimmune disease.